• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Last month
AI

Phar­ma im­ports in­to the US re­turn to nor­mal af­ter March tar­iff stock­pil­ing

Last month
Pharma
Manufacturing

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

Last month
Financing
Deals

Ot­su­ka spells out Phase 3 win in rare kid­ney dis­ease, Ve­ra’s stock takes a hit

Last month
R&D

Bio­phar­ma lead­ers carv­ing a path for the in­dus­try’s LGBTQ+ com­mu­ni­ty

Last month
People
Special

GSK taps Sanofi vet to lead vac­cine R&D; Bris­tol My­ers names head of cor­po­rate af­fairs

Last month
Peer Review

Oma­da Health is go­ing pub­lic at a $1.1B val­u­a­tion

Last month
Financing
Health Tech

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

Last month
China
Pharma

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Last month
Cell/Gene Tx
FDA+

CMS talks health tech

Last month
Health Tech

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

Last month
Cell/Gene Tx
FDA+

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

Last month
R&D
Pharma

Schott Phar­ma's €100M+ Hun­gary ex­pan­sion; An­theia’s $56M Se­ries C raise

Last month
Manufacturing

Cor­cept plots fu­ture for ALS drug that flunked Phase 2, cit­ing sur­vival analy­sis

Last month
R&D

FDA's Prasad ex­plains ra­tio­nale be­hind paus­ing Val­neva's chikun­gun­ya vac­cine in se­niors

Last month
FDA+

Cul­li­nan's deal for T cell en­gager from Chi­na; Kardi­gan buys late-stage heart drug

Last month
News Briefing

Re­genxbio says Duchenne gene ther­a­py im­proved mo­tor skills in five pa­tients

Last month
R&D
Cell/Gene Tx

Ex-Ama­zon em­ploy­ees are bet­ting their new ven­ture changes on­line shop­ping for health­care

Last month
Startups
Health Tech

Anne Wo­j­ci­c­ki and Re­gen­eron set to duke it out in restart­ed 23andMe auc­tion

Last month
Deals
Pharma

Ex­clu­sive: Al­lay reach­es $57.5M Se­ries D mile­stone for post-sur­gi­cal pain drug

Last month
Financing
Startups

Ex­clu­sive: Tech VC Am­pli­fy rais­es $200M for first biotech fund, hires El­liot Her­sh­berg as new part­ner

Last month
Financing
Startups

Dig­i­tal health start­up Vir­ta stakes fees on curb­ing GLP-1 pre­scrip­tions

Last month
Startups
Health Tech

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Last month
Cell/Gene Tx
FDA+

Ex­clu­sive: Af­ter cut­ting most staff, Cas­ma eyes path to clin­ic with its first au­tophagy-boost­ing drug

Last month
R&D
Pharma
First page Previous page 10111213141516 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times